AZN250103P77000
- 0.00
- 0.000.00%
AstraZeneca Newsroom
J&J Lung Cancer Treatment Extends Lives Versus AstraZeneca Drug | NYSE:JNJ
Unusual Options Activity: BP, TPR and Others Attract Market Bets, BP V/OI Ratio Reaches 156.3
J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC
Johnson & Johnson Reports 'Statistically Significant' Data From Trial of Rybrevant, Lazcluze Combination to Treat Lung Cancer
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Asher Bio Announces Clinical Supply Agreement With AstraZeneca To Enable Evaluation Of Etakafusp Alfa In Combination With Rilvegostomig In A Global Phase 1b/2 Study In Non-Small Cell Lung Cancer
Berenberg Maintains AstraZeneca's Rating on Promising 2025 Pipeline
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
AstraZeneca (AZN) Gets a Buy From J.P. Morgan
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
AstraZeneca PLC Stock Flat Friday
AstraZeneca (AZN.US) has initiated a Phase III clinical trial for the PD-1/TIGIT dual antibody.
AstraZeneca (AZN.US) has launched Phase III clinical trials for its PD-1/TIGIT dual antibody.
AstraZeneca Call Volume Above Normal and Directionally Bullish
Unusual Options Activity: NCLH, AZN and Others Attract Market Bets, NCLH V/OI Ratio Reaches 55.6
AstraZeneca Announces Share Capital and Voting Rights Update
AstraZeneca (AZN.US) "Osimertinib" has been approved for a new indication in China.
On January 2nd, the National Medical Products Administration website showed that AstraZeneca (AZN.US)'s application for the new indication of Osimertinib has officially been approved.
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Hutchmed Says China's Medicines Regulator Accepts NDA With Priority Review for Orpathys, Tagrisso Combination